D. Cabañero et al. (Jun 2025)
The Journal of Headache and Pain 26 1
Cold receptor TRPM8 as a target for migraine-associated pain and affective comorbidities
Genetic variations in the Trpm8 gene that encodes the cold receptor TRPM8 have been linked to protection against polygenic migraine,a disabling condition primarily affecting women. Noteworthy,TRPM8 has been recently found in brain areas related to emotional processing,suggesting an unrecognized role in migraine comorbidities. Here,we use mouse behavioural models to investigate the role of Trpm8 in migraine-related phenotypes. Subsequently,we test the efficacy of rapamycin,a clinically relevant TRPM8 agonist,in these behavioural traits and in human induced pluripotent stem cell (iPSC)-derived sensory neurons. We report that Trpm8 null mice exhibited impulsive and depressive-like behaviours,while also showing frequent pain-like facial expressions detected by an artificial intelligence algorithm. In a nitroglycerin-induced migraine model,Trpm8 knockout mice of both sexes developed anxiety and mechanical hypersensitivity,whereas wild-type females also displayed depressive-like phenotype and hypernociception. Notably,rapamycin alleviated pain-related behaviour through both TRPM8-dependent and independent mechanisms but lacked antidepressant activity,consistent with a peripheral action. The macrolide ionotropically activated TRPM8 signalling in human sensory neurons,emerging as a new candidate for intervention. Together,our findings underscore the potential of TRPM8 for migraine relief and its involvement in affective comorbidities,emphasizing the importance of addressing emotional symptoms to improve clinical outcomes for migraine sufferers,especially in females. The online version contains supplementary material available at 10.1186/s10194-025-02082-4.
View Publication
产品号#:
34811
34815
34821
34825
34850
34860
产品名:
AggreWell™ 800 24孔板,1个
AggreWell™ 800 24孔板,5个
AggreWell™ 800 6孔板,1个
AggreWell™ 800 6孔板,5个
AggreWell™ 800 24孔板启动套装
AggreWell™ 800 6孔板启动套装
V. Švubová et al. (Jun 2025)
ImmunoTargets and Therapy 14 1
TGF-β Decreases NK Cell Mobility and Cytotoxic Efficacy in Complex in vitro Models of the Leukemia Microenvironment
Natural killer (NK) cell-based therapies represent a promising approach for acute myeloid leukemia (AML) relapse,yet their efficacy is hindered by immunosuppressive factors such as transforming growth factor beta (TGF-β) in the tumor microenvironment. This study investigated the effects of TGF-β on NK cell cytotoxicity and migration using 2D and 3D co-culture models that mimic the leukemic microenvironment. TGF-β production was evaluated in AML-derived leukemic cell lines and mesenchymal stromal cells (hTERT-MSCs) using ELISA. Bulk RNA sequencing (RNA-seq) was performed to analyze global gene expression changes in TGF-β-treated primary human NK cells. NK cell cytotoxicity and migration were assessed in 2D monolayer and 3D spheroid co-cultures containing hTERT-MSCs and leukemic cells using flow cytometry and confocal microscopy. Both leukemic cells and MSCs produced TGF-β,with increased levels observed in MSCs after co-culture with primary AML blasts. RNA sequencing revealed that TGF-β altered key gene pathways associated with NK cell cytotoxicity,adhesion,and migration,supporting its immunosuppressive role. In functional assays,TGF-β exposure significantly reduced NK cell-mediated cytotoxicity in a time-dependent manner and impaired NK cell infiltration into 3D spheroids,particularly in models incorporating MSCs. Additionally,MSCs themselves provided a protective environment for leukemic cells,further reducing NK cell effectiveness in 2D co-cultures. TGF-β suppresses both NK cell cytotoxicity and migration,limiting their ability to eliminate leukemic cells and infiltrate the bone marrow niche (BMN). These findings provide novel insights into TGF-β–mediated immune evasion mechanisms and provide important insights for the future design of NK-based immunotherapies and clinical trials.
View Publication
产品号#:
34411
34415
34421
34425
34450
34460
产品名:
AggreWell™ 400 24孔板,1个
AggreWell™400 24孔板,5个
AggreWell™ 400 6孔板,1个
AggreWell™ 400 6孔板,5个
AggreWell™400 24孔板启动套装
AggreWell™ 400 6孔板启动套装
M. W. Pocock et al. (Jun 2025)
Nature Cardiovascular Research 4 7
Maturation of human cardiac organoids enables complex disease modeling and drug discovery
Maturation of human pluripotent stem (hPS) cell-derived cardiomyocytes is critical for their use as a model system. Here we mimic human heart maturation pathways in the setting of hPS cell-derived cardiac organoids (hCOs). Specifically,transient activation of 5′ AMP-activated protein kinase and estrogen-related receptor enhanced cardiomyocyte maturation,inducing expression of mature sarcomeric and oxidative phosphorylation proteins,and increasing metabolic capacity. hCOs generated using the directed maturation protocol (DM-hCOs) recapitulate cardiac drug responses and,when derived from calsequestrin 2 ( CASQ2 ) and ryanodine receptor 2 ( RYR2 ) mutant hPS cells exhibit a pro-arrhythmia phenotype. These DM-hCOs also comprise multiple cell types,which we characterize and benchmark to the human heart. Modeling of cardiomyopathy caused by a desmoplakin ( DSP ) mutation resulted in fibrosis and cardiac dysfunction and led to identifying the bromodomain and extra-terminal inhibitor INCB054329 as a drug mitigating the desmoplakin-related functional defect. These findings establish DM-hCOs as a versatile platform for applications in cardiac biology,disease and drug screening. Subject terms: Tissue engineering,Differentiation,Cardiomyopathies
View Publication
产品号#:
05854
05855
100-0483
100-0484
产品名:
mFreSR™
mFreSR™
Hausser Scientificᵀᴹ 明线血球计数板
ReLeSR™
Revach et al. (Jun 2025)
Cell Reports Medicine 6 7
Overcoming resistance to immunotherapy by targeting CD38 in human tumor explants
CD38,an ecto-enzyme involved in NAD + catabolism,is highly expressed in exhausted CD8 + T cells and has emerged as an attractive target to improve response to immune checkpoint blockade (ICB) by blunting T cell exhaustion. However,the precise role(s) and regulation of CD38 in exhausted T cells and the efficacy of CD38-directed therapeutic strategies in human cancer remain incompletely defined. Here,we show that CD38 + CD8 + T cells are induced by chronic TCR activation and type I interferon stimulation and confirm their association with ICB resistance in human melanoma. Disrupting CD38 restores cellular NAD + pools and improves T cell bioenergetics and effector functions. Targeting CD38 restores ICB sensitivity in a cohort of patient-derived organotypic tumor spheroids from explanted melanoma specimens. These results support further preclinical and clinical evaluation of CD38-directed therapies in melanoma and underscore the importance of NAD + as a vital metabolite to enhance those therapies.
View Publication
产品号#:
100-0956
产品名:
ImmunoCult™ XF培养基
M. L. Signorile et al. (Jun 2025)
Signal Transduction and Targeted Therapy 10
Tailoring a novel colorectal cancer stem cell-targeted therapy by inhibiting the SMYD3/c-MYC axis
Cancer stem cells (CSCs) are responsible for colorectal cancer (CRC) chemoresistance,recurrence,and metastasis. Therefore,identifying molecular stemness targets that are involved in tumor growth is crucial for effective treatment. Here,we performed an extensive in vitro and in vivo molecular and functional characterization,revealing the pivotal role of the lysine methyltransferase SET and MYND Domain Containing 3 (SMYD3) in colorectal cancer stem cell (CRC-SC) biology. Specifically,we showed that SMYD3 interacts with and methylates c-MYC at K158 and K163,thereby modulating its transcriptional activity,which is implicated in stemness and colorectal malignancy. Our in vitro data suggest that SMYD3 pharmacological inhibition or its stable genetic ablation affects the clonogenic and self-renewal potential of patient-derived CRC-SCs and organoids by altering their molecular signature. Moreover,we found that SMYD3 stable knock-out or pharmacological inhibition drastically reduces CRC tumorigenicity in vivo and CRC-SC metastatic potential. Overall,our findings identify SMYD3 as a promising therapeutic target acting directly on c-MYC,with potential implications for countering CRC-SC proliferation and metastatic dissemination. Subject terms: Gastrointestinal cancer,Cancer stem cells
View Publication
产品号#:
01700
产品名:
ALDEFLUOR™ 试剂盒
Zhang et al. (Jun 2025)
Experimental & Molecular Medicine 57 6
TGF-β inhibition restores hematopoiesis and immune balance via bone marrow EPCs in aplastic anemia
Aplastic anemia (AA) is a life-threatening bone marrow (BM) failure syndrome characterized by pancytopenia. Recent studies revealed that dysfunctional endothelial progenitor cells (EPCs),critical components of the BM microenvironment,are involved in hematopoietic-dysfunction-related diseases,including AA. However,the mechanism underlying EPC damage in AA remains unknown. Here we find that transforming growth factor-β (TGF-β) signaling is hyperactive in dysfunctional AA EPCs with impaired hematopoietic support and immune regulatory ability,and TGF-β inhibition promotes hematopoiesis and immune rebalance by repairing dysfunctional EPCs. Through impaired EPC and AA murine models,we validated that TGF-β inhibition restores EPC dysfunction to improve hematopoiesis and immune status in vitro and in vivo. RNA sequencing and real-time quantitative polymerase chain reaction provided further validation. These results indicate that dysfunctional BM EPCs with hyperactive TGF-β signaling are involved in AA. TGF-β inhibition promotes multilineage hematopoiesis recovery and immune balance by repairing dysfunctional EPCs,providing a potential therapeutic strategy for AA. Subject terms: Experimental models of disease,Translational research
View Publication
产品号#:
04434
04444
产品名:
MethoCult™ H4434 Classic
MethoCult™ H4434 Classic
M. R. Lidonnici et al. (Jul 2025)
Nature Communications 16
Imbalanced TGFβ signalling and autophagy drive erythroid priming of hematopoietic stem cells in β-thalassemia
The hematopoietic stem cell and multipotent progenitor (HSC/MPP) pool dynamically responds to stress to adapt blood output to specific physiological demands. In β-thalassemia (Bthal),severe anemia and ineffective erythropoiesis generate expansion of erythroid precursors and a chronic stress status in the bone marrow (BM) microenvironment. However,the response to the BM altered status at the level of the HSC/MPP compartment in terms of lineage commitment has not been investigated. Bulk and single-cell RNA-sequencing reveal that Bthal HSCs/MPPs are expanded and activated with enhanced priming along the whole Ery differentiation trajectory. Consistently,HSC/MPP showed an altered TGFβ expression and autophagy transcriptional signatures along with a declined dormancy state. We discovered that the altered TGFβ signaling fosters the Ery potential of HSCs by reducing their autophagic levels,and in vivo stimulation of autophagy is sufficient to rescue the imbalance of the HSC compartment. Our findings identify the interplay between TGFβ and HSC autophagy as a key driver in the context of non-malignant hematopoiesis. Subject terms: Haematopoietic stem cells,Haematological diseases,Autophagy
View Publication
产品号#:
09600
09650
产品名:
StemSpan™ SFEM
StemSpan™ SFEM
T. Mukhtar et al. (Jul 2025)
Nature Communications 16
α7 nicotinic acetylcholine receptors regulate radial glia fate in the developing human cortex
Prenatal nicotine exposure impairs fetal cortical grey matter volume,but the precise cellular mechanisms remain poorly understood. This study elucidates the role of nicotinic acetylcholine receptors (nAChRs) in progenitor cells and radial glia (RG) during human cortical development. We identify two nAChR subunits—CHRNA7 and the human-specific CHRFAM7A—expressed in SOX2+ progenitors and neurons,with CHRFAM7A particularly enriched along RG endfeet. nAChR activation in organotypic slices and dissociated cultures increases RG proliferation while decreasing neuronal differentiation,whereas nAChR knockdown reduces RG and increases neurons. Single-cell RNA sequencing reveals that nicotine exposure downregulates key genes in excitatory neurons (ENs),with CHRNA7 or CHRFAM7A selectively modulating these changes,suggesting an evolutionary divergence in regulatory pathways. Furthermore,we identify YAP1 as a critical downstream effector of nAChR signaling,and inhibiting YAP1 reverses nicotine-induced phenotypic alterations in oRG cells,highlighting its role in nicotine-induced neurodevelopmental pathophysiology. Subject terms: Neuronal development,Developmental neurogenesis,Neural stem cells
View Publication
产品号#:
05854
05855
100-0483
100-0484
产品名:
mFreSR™
mFreSR™
Hausser Scientificᵀᴹ 明线血球计数板
ReLeSR™
M. Koning et al. (Jul 2025)
NPJ Regenerative Medicine 10
Single cell transcriptomics of human kidney organoid endothelium reveals vessel growth processes and arterial maturation upon transplantation
Kidney organoids derived from human induced pluripotent stem cells lack a proper vasculature,hampering their applicability. Transplantation prevents the loss of organoid endothelial cells (ECs) observed in vitro,and promotes vascularization. In this study,we transplanted kidney organoids in chicken embryos and deployed single-cell RNA sequencing of ~12,000 organoid ECs to delineate their molecular landscape and identify key changes associated with transplantation. Transplantation significantly altered EC phenotypic composition. Consistent with angiogenesis,proliferating EC populations expanded 8 days after transplantation. Importantly,ECs underwent a major vein-to-arterial phenotypic shift. One of the transplantation-specific arterial EC populations,characterized by laminar shear stress response and Notch signalling,showed a similar transcriptome as human fetal kidney arterial/afferent arteriolar ECs. Consistently,transplantation-induced transcriptional changes involved proangiogenic and arteriogenic SOX7 transcription factor upregulation and regulon enrichment. These findings point to blood flow and candidate transcription factors such as SOX7 as possible targets to enhance kidney organoid vascularization. Subject terms: Nephrons,Transcriptomics,Angiogenesis,Angiogenesis,Stem cells,Stem-cell differentiation
View Publication
产品号#:
05270
05275
产品名:
STEMdiff™ APEL™2 培养基
STEMdiff™ APEL™2 培养基
F. Huang et al. (Jul 2025)
Journal of Nanobiotechnology 23
Early-life exposure to polypropylene nanoplastics induces neurodevelopmental toxicity in mice and human iPSC-derived cerebral organoids
Nanoplastics (NPs) are emerging environmental pollutants that pose growing concerns due to their potential health risks. However,the effects of inhaled NP exposure during pregnancy on fetal brain development remain poorly understood. In this study,we investigated the impact of maternal exposure to polypropylene nanoplastics (PP-NPs) on fetal brain development and neurobehavioral outcomes in a mouse model and further explored its mechanism in human cerebral organoids. Maternal exposure to PP-NPs significantly impaired neuronal differentiation and proliferation in the fetal cortex. Neurobehavioral assessments revealed significant deficits in offspring following maternal exposure,including impaired spatial memory,reduced motor coordination,and heightened anxiety-like behavior. Furthermore,human brain organoids exposed to PP-NPs exhibited reduced growth and neuronal differentiation,with significant downregulation of key neuronal markers such as TUJ1,MAP2,and PAX6. Transcriptomic analysis identified alterations in gene expression,particularly in neuroactive ligand-receptor interaction pathway. Molecular docking and fluorescence co-localization analysis further suggested CYSLTR1 and PTH1R as key molecular targets of PP-NPs. These findings provide novel insights into the toxicological effects of NPs on the developing brain and emphasize the need for preventive measures to protect fetal neurodevelopment during pregnancy. The online version contains supplementary material available at 10.1186/s12951-025-03561-1.
View Publication
产品号#:
08570
产品名:
STEMdiff™ 脑类器官试剂盒
V. Ramar et al. (Jul 2025)
Cell Communication and Signaling : CCS 23
TRIM21 functions as an oncogene in glioblastoma by transactivating FOSL1 and promoting the ubiquitination of p27
Our previous studies demonstrated that FOSL1 promotes glioblastoma (GBM) progression and stemness through pathways such as STAT3 and NF-κB signaling. Recently,we identified that FOSL1 physically interacts with the nuclear E3 ligase TRIM21. This study investigates the role of TRIM21 in GBM,including its interaction with FOSL1,its regulation of FOSL1 transactivation,and its ubiquitination-mediated degradation of tumor suppressor p27. Immunoprecipitation assays were used to evaluate the interactions between TRIM21,FOSL1,and p27. TRIM21 expression was manipulated through overexpression and siRNA-mediated knockdown to assess its effects on p27 levels and ubiquitination. TCGA and CGGA datasets were analyzed to explore correlations between TRIM21 expression,glioma subtypes,and patient survival. Glioma cell proliferation (MTT and colony formation) and invasion (transwell assays) were evaluated following TRIM21 manipulation. Immunohistochemistry on glioma patient tissue microarray (TMA) assessed TRIM21 expression and its association with FOSL1,IDH status,and glioma grade. The role of nuclear TRIM21 in FOSL1 promoter transactivation was analyzed via AP-1 binding sites. TCGA and CGGA revealed that TRIM21 is highly expressed in GBM,particularly in the mesenchymal subtypes,and correlates with poor survival outcomes. Functional assays demonstrated that TRIM21 enhances glioma cell proliferation and invasion. Immunohistochemistry confirmed elevated TRIM21 levels in gliomas,positively correlating with FOSL1 expression and glioma grade,and inversely correlating with IDH1 wild-type status. Mechanistically,TRIM21 physically interacts with FOSL1 and p27,driving tumorigenesis by transactivating FOSL1 via AP-1 binding sites and promoting p27 ubiquitination and degradation. These functions are mediated through TRIM21’s RING domain for p27 degradation and its PRYSPRY domain for FOSL1 regulation. TRIM21 functions as an oncogene in GBM by degrading the tumor suppressor p27 and promoting FOSL1 transactivation. These findings highlight TRIM21 as a promising therapeutic target in GBM. The online version contains supplementary material available at 10.1186/s12964-025-02325-6.
View Publication
产品号#:
01700
01702
产品名:
ALDEFLUOR™ 试剂盒
ALDEFLUOR™检测缓冲液
F. D. Mitri et al. (Jul 2025)
Journal of Experimental & Clinical Cancer Research : CR 44 1
Inhibition of autophagy enhances the antitumor efficacy of T/CAR T cell against neuroblastoma
Neuroblastoma (NB) is the most common extracranial solid tumor in children characterized by poor immune infiltration and resistance to adaptive immunity,contributing to its limited response to immunotherapy. A key mechanism underlying immune evasion in cancer is autophagy,a cellular process that plays many roles in cancer by supporting tumor survival and regulating immune interactions. In this study,we investigate the impact of autophagy inhibition on NB tumor growth,immune modulation,and the efficacy of immunotherapy. Using both murine and human NB cell lines,we demonstrate that genetic and pharmacological inhibition of autophagy significantly reduces 3D spheroid growth and upregulates major histocompatibility complex class I (MHC-I) expression. In vivo studies further confirm that targeting autophagy suppresses tumor progression and promotes immune infiltration into the tumor. Notably,we observe a significant increase in CD8 + T cell recruitment and activation,suggesting that autophagy inhibition reshapes the immune landscape of NB,rendering it more susceptible to immune-mediated clearance. Crucially,autophagy inhibition also sensitizes NB cells to T cell-mediated cytotoxicity and enhances the therapeutic efficacy of GD2.CAR T-cell therapy. In vitro co-culture assays reveal increased CAR T cell-mediated tumor killing upon autophagy blockade,while in vivo models show prolonged tumor control and improved survival in treated mice compared to CAR T-cell therapy alone. These findings highlight autophagy as a key regulator of immune evasion in NB and suggest that its inhibition could serve as a promising therapeutic strategy to enhance immune recognition and improve the efficacy of immunotherapy. The online version contains supplementary material available at 10.1186/s13046-025-03453-0.
View Publication